Bilateral first rib resection and scalenectomy is effective for treatment of thoracic outlet syndrome.
OBJECTIVE
Because of the small numbers of thoracic outlet syndrome (TOS) patients treated with bilateral first rib resection and scalenectomy (FRRS), this patient subset has not been well studied. We examined a large cohort of TOS patients who underwent bilateral FRRS to evaluate patient characteristics and outcomes.


METHODS
Patients treated with bilateral FRRS at Johns Hopkins Medical Institutions from 2003 to 2012 were identified by review of a prospectively maintained database. Statistical analysis compared patients with unilateral and bilateral FRRS and bilateral patients with different TOS indications.


RESULTS
Fifty-three patients underwent bilateral FRRS with a mean follow-up of 11.4 months. Average time between operations was 17.0 months (range, 5.1-59.8 months). Compared with 408 unilateral FRRS patients, bilateral patients were younger (30 vs 35 years; P = .012), with no significant difference in gender. Among patients with dual-sided FRRS, 25 (47%) had bilateral neurogenic symptoms, 2 (4%) had bilateral arterial symptoms, and 26 (49%) had venous symptoms with the first side due to intermittent compression in 5 (second side: four, intermittent compression; one, neurogenic) and effort thrombosis in 21 (second side: 9, effort thrombosis; 8, intermittent compression; 4, neurogenic). Ten patients had prophylactic FRRS to prevent contralateral venous or arterial thrombosis, and eight had cervical ribs. Compared with neurogenic patients, venous patients were younger (25 vs 35 years; P < .001), with a trend toward more competitive athletes (seven venous vs two neurogenic). Symptomatic restenosis requiring dilation occurred after four FRRS for venous symptoms at a mean of 32.4 months, and rethrombosis occurred after four FRRS at a mean of 4 weeks (one treated with warfarin, three with tissue plasminogen activator), all on the primary side. Overall, 88% of FRRS for symptomatic TOS led to resolved symptoms at last follow-up.


CONCLUSIONS
Bilateral FRRS is an effective method for treatment of TOS. Venous bilateral patients more often are younger, are competitive athletes, and require close postoperative monitoring for recurrent stenosis and thrombosis.
Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins Medical Institutions, Baltimore, Md. Electronic address: danielle.rochlin@jhmi.edu.
Danielle H
DH
Rochlin
Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins Medical Institutions, Baltimore, Md.
Megan S
MS
Orlando
Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins Medical Institutions, Baltimore, Md.
Kendall C
KC
Likes
Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins Medical Institutions, Baltimore, Md.
Carly
C
Jacobs
Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins Medical Institutions, Baltimore, Md.
Julie A
JA
Freischlag
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000800:Angioplasty, Balloon; D000925:Anticoagulants / Q000627:therapeutic use; D002648:Child; D003251:Constriction, Pathologic / Q000209:etiology / Q000628:therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009334:Neck Muscles / Q000601:surgery*; D012008:Recurrence; D012189:Retrospective Studies; D012272:Ribs / Q000601:surgery*; D013348:Subclavian Artery; D013350:Subclavian Vein; D013901:Thoracic Outlet Syndrome / Q000150:complications / Q000601:surgery*; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use; D055815:Young Adult
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin; D010959:Tissue Plasminogen Activator